Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mineralocorticoid Receptor Antagonists in Managing Hypertension: A Link With Diurnal Patterns of Blood Pressure.

Journal of cardiovascular pharmacology·2026
Same author

ADAM17 as a promising molecular target for organ protection in antihypertensive therapy.

American journal of hypertension·2026
Same author

Landiolol in patients with supraventricular arrhythmias: real-world efficacy and safety.

European heart journal. Acute cardiovascular care·2026
Same author

Retraction: The utility of biomarker risk prediction score in patients with chronic heart failure.

Clinical hypertension·2026
Same author

Early predictors of carotid atherosclerosis in patients with type 2 diabetes mellitus.

World journal of diabetes·2025
Same author

New Cardioprotective Frontiers in Double Inhibition With SGLT2 and PCSK9 in Cancer Survivors.

Journal of cardiovascular pharmacology·2025

Related Experiment Video

Updated: Feb 15, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Circulating Biomarkers in Heart Failure.

Alexander E Berezin1

  • 1Internal Medicine Department, State Medical University of Zaporozhye, Zaporozhye, Ukraine. dr_berezin@mail.ru.

Advances in Experimental Medicine and Biology
|February 3, 2018
PubMed
Summary

Biomarkers aid heart failure (HF) diagnosis and treatment. Further research is needed to refine HF risk stratification and disease management strategies using these vital biological markers.

Keywords:
Biomarker guided-therapyBiomarkersHeart failurePredictionStratification

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Experiment Videos

Last Updated: Feb 15, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Medicine

Background:

  • Biological markers are crucial for diagnosing, stratifying risk, and guiding therapy in heart failure (HF).
  • Understanding of biomarker capabilities in relation to HF pathogenesis and clinical outcomes is growing.
  • Current HF guidelines lack comprehensive strategies for exclusion, risk stratification, and disease evolution management.

Purpose of the Study:

  • To discuss the role of biomarker-based approaches in improving HF diagnosis.
  • To explore the use of biomarkers for in-depth risk stratification in HF patients.
  • To highlight how biomarkers can enable individualized treatment targeting for HF.

Main Methods:

  • Literature review of current biomarker research in heart failure.
  • Analysis of existing clinical guidelines and their limitations.
  • Synthesis of evidence on biomarker utility in HF diagnosis, risk assessment, and treatment.

Main Results:

  • Biomarkers offer significant potential for enhancing the accuracy of HF diagnosis.
  • Biomarker profiles can provide deeper insights into HF risk stratification.
  • Biomarker data supports the development of personalized therapeutic strategies for HF.

Conclusions:

  • Biomarker-based strategies are essential for advancing HF patient care.
  • Further development is required to fully integrate biomarkers into HF management protocols.
  • Optimizing biomarker utilization will lead to more precise diagnosis, risk assessment, and tailored treatments for heart failure.